Genotypic and Phenotypic Predictors of the Magnitude of Response to Tenofovir Disoproxil Fumarate Treatment in Antiretroviral‐Experienced Patients
Results from 2 placebo-controlled intensification trials of tenofovir disoproxil fumarate (DF) in treatmentexperienced human immunodeficiency type 1 (HIV-1)-infected patients (n = 332) were integrated to determine the effects of resistance at baseline on HIV-1 RNA response. In these trials, there wa...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Ingarihi |
| I whakaputaina: |
2004
|
| Urunga tuihono: | https://doi.org/10.1086/381784 https://academic.oup.com/jid/article-pdf/189/5/837/6022789/189-5-837.pdf |
| Ngā Tūtohu: |
Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|